

Special Issue

High-Risk Atrial Fibrillation in Patients with Cardiovascular Disease: Diagnosis, Comprehensive Risk Assessment, Comorbidities, and Anticoagulation Strategies

Message from the Guest Editors

This proposed Special Issue aims to address this critical knowledge deficit by soliciting original research and comprehensive reviews on various aspects pertinent to high-risk AF patients. We invite submissions focusing on, but not limited to, the following key areas:

- Thromboembolic Risk: Methodologies for the accurate assessment of thromboembolic risk in this specific patient population.
- Cardiovascular Comorbidity: Investigation into impact of associated cardiovascular comorbidities within the high-risk AF cohort.
- Associated Factors: Identification and characterization of genetic factors associated with an increased likelihood of AF development and adverse cardiovascular events.
- AF Burden Assessment: Advanced methodologies for quantifying AF burden, including the role and implications of device-detected atrial fibrillation (DDAF).
- Treatment Strategies: Evaluation of the efficacy and safety of diverse therapeutic approaches, encompassing initiatives such as CARE-AF and various anticoagulation strategies, tailored for this high-risk population.

Guest Editors

Dr. Silvia Reverté-Villarroya

Advanced Nursing Research Group, Medicine and Health Sciences, University Rovira i Virgili, 43002 Tarragona, Spain

Dr. José-Luis Clúa-Espuny

Primary Health-Care Centre, Institut Català de la Salut, Primary Care Service (SAP) Terres de l'Ebre, 43500 Tortosa, Spain

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/252955

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).